Clinical Trial Update: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of IDE161, a PARG inhibitor, is recruiting in patients with several solid tumor types including breast, ovarian, and various lung cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Extensive-stage Small Cell Lung Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• IDE161

Snippet

Sponsor: IDEAYA Biosciences | Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 | Status: RECRUITING